Navigation Links
Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
Date:9/4/2007

SAN DIEGO, Sept. 4 /PRNewswire/ -- Takeda San Diego announced today that Keith Wilson, Ph.D. has been named president and chief scientific officer (CSO). In this position, he is responsible for overseeing all activities related to Takeda San Diego, Takeda Pharmaceutical Company Limited's U.S.-based drug discovery company.

"Dr. Wilson has been an important part of Takeda San Diego for several years and brings a wealth of scientific excellence to Takeda," said Shigenori Ohkawa, Ph.D., general manager, pharmaceutical research division, Takeda Pharmaceutical Company Limited. "His leadership has been instrumental in focusing the company on drug discovery and building the Takeda San Diego pipeline, and we look forward to his vital contributions in this new role."

Before being named president and CSO at Takeda San Diego, Dr. Wilson served dual roles as vice president of structural biology and vice president of business development. Prior to joining Takeda, he also spent a decade with Vertex Pharmaceuticals co-leading drug discovery programs and significant alliance projects.

Dr. Wilson has formal training in protein X-ray crystallography, and has a doctorate degree in physics from the University of Oregon and a bachelor's degree in physics from Colby College, where he graduated magna cum laude and was awarded the William A. Rogers prize in physics. Dr. Wilson is a contributing author on more than 30 peer-reviewed publications and co-inventor of six issued U.S. patents covering multiple drug candidates.

About Takeda San Diego, Inc.

Takeda San Diego is Takeda's first U.S.-based discovery research operation. Takeda San Diego achieves an advantage in drug discovery by leveraging its leading structural biology capabilities to determine the three dimensional structures of drug targets ahead of competitors and then uses these structures to efficiently create best-in-class drug candidates to treat diabetes, cancer, and other important diseases. Visit http://www.takedasd.com to learn more.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.


'/>"/>
SOURCE Takeda Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. CEO Wilson Defines GEs Health-IT Customer
2. Bruce Maas named CIO at UW-Milwaukee
3. Three finalists named for UW-Madison CIO
4. Eight lawmakers named to Speakers IT task force
5. Hospital named for Madame Curie installs TomoTherapy system
6. Two UW-Madison professors named to National LambdaRail Networking Research Council
7. UW researcher named top innovator
8. Alzheimers drug firm and more winners named in Wisconsin business-plan contest
9. Inacom named Microsofts favorite learning solutions partner of the year
10. Five Wisconsin CIOs named top in nation
11. Deltanoid named to top-15 list of biotech companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... KONG, Feb. 24, 2017 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its unaudited financial results for the third ... ended December 31, 2016. Third Quarter of ... third quarter of fiscal 2017 increased by 18.6% to ...
(Date:2/24/2017)... VWR), the leading global independent provider of product and service ... results for the fourth quarter and full year ended December ... record quarterly net sales of $1.13 billion, up 1.6% year-over-year, ... 4Q16 EMEA-APAC segment net sales increased 0.4%, up ... increased 2.5%, or down 0.9% on an organic basis, driven ...
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
Breaking Biology Technology:
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
Breaking Biology News(10 mins):